Use of drug-eluting balloon coronary intervention prior to living donor kidney transplantation

BMC Cardiovascular Disorders

Case Report

Tobias Kammerer¹  Markus Rehm¹  Florian Weis²  Christian Kupatt-Jeremias³  Markus Guba⁴  Manfred Stangl⁴  Andres Beiras-Fernandez⁵ 

[1] Department of Anesthesiology, University of Munich, Großhadern, Marchioninistrasse 15, 81377, Munich, Germany;Department of Anesthesiology, University of Munich, Großhadern, Marchioninistrasse 15, 81377, Munich, Germany;Department of Anaesthesiology, Clinic Fürstenfeldbruck, Dachauer Strasse 33, D-82256, Fürstenfeldbruck, Germany;Department of Cardiology, University of Munich, Großhadern, Marchioninistrasse 15, 81377, Munich, Germany;Department of Surgery, University of Munich, Großhadern, Marchioninistrasse 15, 81377, Munich, Germany;Department of Thoracic and Cardiovascular Surgery, University Hospital, JW Goethe-University, Theodor–Stern–Kai 7, 61590, Frankfurt, Germany;

关键词: Chronic Obstructive Pulmonary Disease;    Leave Anterior Descend;    Prasugrel;    Bare Metal Stents;    Eptifibatide;   

DOI  :  10.1186/1471-2261-14-112

 received in 2014-01-30, accepted in 2014-08-19,  发布年份 2014

来源: Springer

【 摘 要 】

BackgroundKidney transplantation is the gold standard of therapy in patients with terminal renal insufficiency. Living donor transplantation is a well-established option in this field. Enlarging the donor’s pool implicates the acceptance of an increased rate of comorbidities. Among them, coronary artery disease is a growing problem. An increasing number of patients, undergoing living donation, receive antiplatelet therapies due to coronary disease.Case presentationHere we report about the perioperative treatment with a drug-eluting balloon in a patient with major cardiac risk factors who underwent kidney transplantation.ConclusionAt the current time no recommendation can be given for the routine use of drug-eluting balloons.

【 授权许可】

Unknown   
© Kammerer et al.; licensee BioMed Central Ltd. 2014. This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.